8-K filed October 7, 2024, 7:59 PM ET ticker DWTX CIK 0001818844

M&A confidence high sentiment neutral materiality 0.85

Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics

Dogwood Therapeutics, Inc.

Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.
Received $19.5M loan from CKLS affiliate; $16.5M funded at close, $3M due Feb 2025.
Existing shareholders get CVR entitling to 87.75% of future Halneuron milestone payments over 7 years.
Board: Richard Burch resigned; Alan Yu and Melvin Toh (CKLS) appointed; Angela Walsh promoted to CFO.
Name change to Dogwood Therapeutics; stockholder meeting required for conversion and reverse split.

item 1.01 item 5.03 item 2.01 item 3.02 item 3.03 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Angela Walsh

Chief Financial Officer

DWTX · Dogwood Therapeutics, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024

Departed

Richard Burch

Director

DWTX · Dogwood Therapeutics, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024

Appointed

Melvin Toh

Director

DWTX · Dogwood Therapeutics, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

and Melvin Toh as a director of the Company

Appointed

Alan Yu

Director

DWTX · Dogwood Therapeutics, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

appointed Alan Yu as a director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Angela Walsh changed role as Chief Financial Officer at Dogwood Therapeutics, Inc..

Action: promoted
Role: Chief Financial Officer

Exact text from the filing

promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Burch resigned as Director at Dogwood Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Melvin Toh was appointed as Director at Dogwood Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

and Melvin Toh as a director of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Yu was appointed as Director at Dogwood Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Alan Yu as a director of the Company

View on SEC.gov

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-013167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.